BeiGene

#News for #Investors and #Media: Our BTK Inhibitor has received approval in the Philippines for the treatment of chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). This approval marks the fourth indication of our treatment for blood cancer in the country. #CLL #MZL #BloodCancer

Mark Lanasa, our CMO of Solid Tumors, joined industry peers this week at the Fierce Biotech Summit where he shared the rationale behind how our expansive pipeline supports our mission to develop more accessible and affordable cancer medicines. #FierceBiotechSummit 

I was thrilled to join the panel, "Building a Culture of Sustainability in Pharma" at BioWeek Boston with James Connelly, Byron Austin and Manu Juneja. We tackled key issues such as avoiding greenwashing, the importance of third-party verification, and the challenges of sustainable practices in pharma and biotech. At BeiGene, we recognize that human health and the health of the planet are intrinsically linked, and we are committed to mitigating our environmental impacts. With the health sector generating 4-5% of global emissions, it’s clear we must work together to create a greener future through sustainable innovation and collaboration. #Sustainability #Pharma #Biotech #ESG

We’re honored to be awarded the 2024 Corporate Leadership Award from the Lymphoma Research Foundation at their Annual Gala in New York City. This recognition highlights our commitment to advancing bold cancer research, developing next-generation therapies, and supporting patients with medicines that are both affordable and accessible worldwide. Thank you to the Foundation for this accolade. We are grateful to work alongside you to bring more hope and better outcomes to patients with lymphoma. Read more here: https://bit.ly/3N9dKGL #PatientsFirst #Lymphoma

Did you know 1 in 8 women in the U.S. will develop breast cancer in her lifetime? It is the second leading cause of cancer death among women in the country.   We believe awareness is key to empowering individuals to make informed health decisions. Breast Cancer Awareness Month serves as an opportunity to honor those affected by this disease and to reflect on the latest advancements in research, prevention, and treatment. Let’s come together to spread knowledge and support one another! #BreastCancerAwarenessMonth

Last week, we celebrated moving to a new BeiGene office in Bangkok with a traditional "Merit-Making" ceremony, which was a special moment for our local team in Thailand. Thailand has a population of 70 million people, and the #cancer burden is immense with around 184,000 new cancer cases each year and 119,000 people dying from cancer annually. With a per capita GDP of just $7,000 USD, affordable #access to high-quality #medicine remains extremely challenging for cancer patients, their families, and doctors. In Thailand, we are determined to have an impact and make a difference. Our foundational belief is that WHERE you live should not determine IF you live ❤️. We’re proud to have a team of passionate and dedicated people committed to changing the trajectory of cancer care in Thailand. Thank you to Supapun Tungpoonsupsiri, Pintip Roongadulpisan, Kannika Numuang and Ratana Kulkantrakorn for your clear vision and #leadership as we build our organization and work towards faster, broader access to high-quality medicine for cancer patients in Thailand (the 'Land of Smiles').   Cancer has no borders. Neither do we. 🌏

Yesterday at the CLL Horizons, we hosted an interactive workshop with patient representatives from 17 countries focused on uncovering the unmet needs for people living with chronic lymphocytic leukemia (CLL).   Thank you Dr. Lydia Scarfo, Dr. Christina Karamanidou, and Jana Pelouchova for leading the discussions. Your insights are invaluable in enhancing support for patients. We look forward to continuing this dialogue and working together with the community to empower CLL patients. CLL Advocates Network #CLL #CLLHZ24 #Patvocates

We recently hosted our first Global Compliance Week, bringing together team members from around the world for a range of engaging sessions tailored to each region. These interactive activities centered on critical compliance principles, including anti-bribery, anti-corruption, and ethical decision-making. This week served as an opportunity for reflection on the importance of ethical behavior in our everyday operations and reinforced our shared commitment to upholding the highest compliance standards. We’re excited about the strong engagement and positive feedback from colleagues and look forward to continuing fostering a culture of integrity and trust across our organization.

As part of our ongoing commitment to diversity, equity, inclusion, and belonging (DEIB), we celebrate all cultures and communities, including the rich contributions of Hispanic and Latino heritage.      Earlier this week, we hosted a fireside chat featuring our colleague Frances Pena and her sister, Claudia Pena, Executive Director of For Freedoms and Faculty at UCLA School of Law & Gender Studies Department. They shared valuable cultural insights and discussed the importance of recognizing Hispanic and Latino contributions both within our company and in the wider community.    Learn more about our DEIB initiatives at https://bit.ly/3RhIrfx.  #HispanicHeritageMonth 

Our Chief Medical Officer for Hematology Mehrdad Mobasher shared his perspectives on the evolving chronic lymphocytic leukemia (#CLL) treatment landscape in a discussion with Professor Stephan Stilgenbauer on Oncology Central. They discuss the latest clinical data and research on hematological malignancies presented by BeiGene at #ASCO2024 and #EHA2024. https://bit.ly/3Y0grRa